QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Brolucizumab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Brolucizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why should aggregate analyses of retinal vasculitis and retinal vascular occlusion preserve the inflammatory phenotype?

To ensure that all ocular events are counted as one broad category Because clinically specific patterns may be obscured if these events are indiscriminately combined with all inflammation or vascular events Because inflammatory findings are never relevant to vascular occlusion To avoid reviewing imaging and clinical narratives

Question 2 of 10 Which distinction is most important when reviewing a case labelled simply as uveitis after intravitreal brolucizumab?

Whether the patient received treatment in a hospital or clinic Whether the inflammation is anterior, vitreous or posterior and whether retinal vasculitis or occlusion is present Whether the patient had previously used an oral antibiotic Whether the injection volume was described as large or small

Question 3 of 10 How should retinal vasculitis and retinal vascular occlusion be distinguished in case assessment?

Vasculitis refers to impaired blood flow, whereas occlusion refers to inflammation of vessel walls Vasculitis describes inflammatory involvement of retinal vessels, whereas occlusion describes impaired retinal blood flow They are interchangeable terms and should always be combined into one diagnosis Vasculitis is limited to venous disease, whereas occlusion is limited to arterial disease

Question 4 of 10 Which statement best captures the longitudinal nature of brolucizumab benefit-risk evaluation?

Once efficacy is demonstrated, later safety information cannot alter clinical use A medicine may retain meaningful efficacy while new safety information changes patient selection, monitoring and urgent evaluation requirements Only pre-authorisation trial data should be used in periodic evaluation New safety information automatically means that efficacy is no longer clinically relevant

Question 5 of 10 Which combination best describes brolucizumab's molecular and therapeutic classification?

A full-length IgG antibody administered intravenously to inhibit systemic VEGF-A A humanised single-chain antibody fragment administered intravitreally to neutralise VEGF-A A recombinant receptor fusion protein administered subcutaneously to block VEGF receptors A small-molecule kinase inhibitor administered orally to suppress angiogenesis

Question 6 of 10 What is the principal pharmacodynamic consequence of brolucizumab binding VEGF-A?

Increased retinal vascular permeability to improve drug diffusion Activation of endothelial-cell survival pathways and new-vessel formation Reduction of VEGF-A-mediated permeability and pathological angiogenic signalling Direct destruction of abnormal retinal vessels by an immune-mediated mechanism

Question 7 of 10 Which inspection question most directly tests whether an organisation has learned from the brolucizumab post-authorisation safety experience?

Can the organisation count all reports containing the word visual? Can the organisation distinguish retinal vasculitis or vascular occlusion from infectious, mechanical and nonspecific visual events using objective clinical information? Can the organisation confirm that every patient received the same injection interval? Can the organisation identify only systemic adverse events?

Question 8 of 10 Which follow-up information would provide the strongest support for evaluating suspected retinal vasculitis?

Angiography findings, inflammatory features, vessel involvement, occlusive status and visual outcome The patient's preferred injection appointment time The number of systemic medicines prescribed in the previous year A general statement that the patient felt unwell after treatment

Question 9 of 10 Which statement best reflects the regulatory significance of post-authorisation reports involving retinal vasculitis and retinal vascular occlusion?

They were treated as evidence that all anti-VEGF therapies are contraindicated They led to strengthened warnings and risk-minimisation measures for important identified risks They demonstrated that pre-authorisation clinical trials had no scientific value They resulted only in a change to batch-release testing

Question 10 of 10 A retinal tear occurs shortly after an intravitreal injection. Which causal assessment is most consistent with the article?

It should be attributed automatically to VEGF-A neutralisation It should be considered potentially procedure-related or disease-related and investigated using retinal and procedural details It should be classified as systemic thromboembolism It should be excluded because retinal tears are not relevant to pharmacovigilance

Professional Knowledge Assessment: Brolucizumab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings